ClinicalTrials.gg
TerminatedNCT02976038Updated Dec 17, 2021Results posted

Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)

A Phase 2 interventional study of elamipretide in Primary Mitochondrial Disease, sponsored by Stealth BioTherapeutics Inc.. Terminated at 4 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2021-12-17.

Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Registration trial did not meet the primary end points

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.

Enrollment
30th of 50
28 · median 38
Started
2016
with 4 others
Phase 2
16 of 83
1 open now
Registered
47th of 83
by date
Lead sponsor
3 of 83
Stealth BioTherapeutics Inc.

Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 30th largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2016, is one of 16 in phase 2, and was the 47th registered.

Mitochondrial Diseases

189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.

Browse Mitochondrial Diseases studies →

Open to participants now

20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Mitochondrial Diseases with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 Open-Label extension study to evaluate the long term safety and tolerability of daily elamipretide injections in patients with genetically confirmed Primary Mitochondrial Disease who previously participated in the SPIMM-202 Clinical Trial

Read the detailed description

This open-label, non-comparative, extension trial will enroll subjects with genetically confirmed PMD who have completed the End-of-Study Visit in the SPIMM-202 trial. Subjects who do not discontinue or withdraw from the trial will receive treatment with 40 mg SC elamipretide for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.

03

Conditions studied

  • Primary Mitochondrial Disease

Keywords

  • Primary Mitochondrial Disease
  • Stealth
  • elamipretide
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Investigator determines the subject can, and subject agrees to, adhere to the trial requirements for the length of the trial including self-administration (by subject or trained caregiver) of the study drug
  • Subject completed the End-of-Study Visit in SPIMM-202

Exclusion criteria

Exclusion Criteria:

  • Subject has any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all trial requirements
  • Subject has received any compound (excluding elamipretide) and/or has participated in another interventional clinical trial within 30 days prior to the SPIMM-203 Baseline Visit (excluding SPIMM-202) or is concurrently enrolled in any non-interventional research of any type judged to be scientifically or medically incompatible with the trial as deemed by the Investigator in consultation with the Sponsor
  • Subject experienced an adverse reaction attributed to study drug resulting in permanent discontinuation of study drug in the SPIMM-202 trial.
  • Female subjects who are pregnant, planning to become pregnant, or lactating
  • Subject has undergone an in-patient hospitalization within the 1 month prior to the SPIMM-203 Baseline Visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    elamipretide

    Open-label once daily subcutaneous injection of 40mg elamipretide

    Drug: elamipretide

Interventions

  • 40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.

06

What researchers measure

Primary outcomes

  1. Distance Walked on Six Minute Walk Test

    Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

Secondary outcomes

  1. EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)

    EuroQol 5 dimensions 5 levels (EQ-5D-5L) by visit. Count of participants per arm, or severity level of dimension. Measures 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Score ranges from 5-25 with lower score=better outcome, and higher score means a worse outcome.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  2. Euroquol Visual Analog Scale

    Euroquol Visual Analog Scale (EQ VAS): A patient-reported measure. The visual scale is numbered from 0 to 100, participants are directed as follows: "100 means the best health you can imagine, 0 means the worst health you can imagine. Mark an X on the scale to indicate how your health is TODAY." Higher scores mean better outcome, lower scores mean worse outcome.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  3. NeuroQOL Fatigue Questionnaire

    Change from baseline in NeuroQOL Fatigue Questionnaire by visit. Questionnaire is comprised of 8 questions measuring participants incidence of fatigue affecting activities of daily living. Participants respond by choosing one of the following: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always, with a lower score meaning a better outcome with fatigue affecting participant less, and high score meaning a worse outcome, with fatigue affecting the participant more. Total raw scores range from 8-40. Scores were converted to percentages: range0-100%. Change from baseline score: negative number means improved from baseline, positive number means worsened compared to baseline.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  4. Patient Global Assessment : Categorical

    Patient Global Assessment \[PGA\] Score by Visit, count of participants. Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  5. Patient Global Assessment: Continuous Variable

    Patient Global Assessment \[PGA\] Score by Visit, Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, lower score means worse outcome.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  6. Work Limitations Questionnaire

    Work Limitations Questionnaire by visit. Comprised of 25 items, in 4 categories, or demands: Mental/Interpersonal, Output Tasks, Physical Tasks, and Time Management, measuring the degree to which employed individuals are experiencing limitations on-the-job due to their health problems, and health-related productivity loss. 1= All of the time (100%), 2= most of the time, 3=some of the time (about 50%), 4=slight bit of time, 5=none of the time (0%), 6=does not apply to my job. (Presenteeism). The WLQ items ask respondents to rate their level of difficulty or ability to perform specific job demands. Scale score range from 0 (limited none of the time=better outcome) to 100 (limited all of the time= worse outcome) and represent the reported amount of time in the prior two weeks respondents were limited on-the-job.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  7. Physician Global Assessment Score (PhGA) by Visit

    Physician Global Assessment- Mean Score by visit. PGA Scale asks physician to rate participant's current health status as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means lower health status, worse outcome; lower score means better health status, better outcome.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  8. Physician Global Assessment (PhGA): Categorical

    Physician Global Assessment \[PhGA\] Score by Visit, Physician-reported current health status by visit. PhGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  9. PMMSA Individual Items

    The PMMSA is a patient-reported outcome measure, assessing a participant's "worst feeling" of 10 symptoms during the last 24 hours: tiredness at rest, tiredness during activities, muscle weakness at rest, muscle weakness during activities, balance, vision, abdominal discomfort, muscle pain, numbness, and headache using a 4-point scale: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Max Score =40= worse outcome, Min score= 10= better outcome on scale. PMMSA Individual Items shows number or participants with mild, moderate, severe or no symptoms at all.

    Time frame: Baseline, Week 13, 26, 52, 104, 156, End of Study (Week 160)

  10. Total Fatigue Score_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

    Change from baseline in the Total Fatigue score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 4 symptoms: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q1 to Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

  11. Total Fatigue Score During Activities_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

    Change from baseline in the Total Fatigue during Activities score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 2 symptoms: Tiredness during activities, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q2 and Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 2-8; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.

    Time frame: Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks

07

Results

Posted Dec 17, 2021

Participant flow

Participant flow — Overall Study
MilestoneElamipretide
Started28
Completed0
Not completed28
Withdrew: Physician decision22
Withdrew: Withdrawal by subject3
Withdrew: Lost to follow-up2
Withdrew: Adverse event1

Outcome measures

PrimaryDistance Walked on Six Minute Walk Test

Change From Baseline in Distance Walked (meters) on the Six-Minute Walk Test by Visit

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Mean · meters
Distance Walked on Six Minute Walk Test
metersElamipretide
Week 133.6 ± 52.68
Week 26-8.6 ± 56.33
Week 52-17.6 ± 70.60
Week 78-26.2 ± 73.17
Week 104-20.9 ± 77.78
Week 130-18.9 ± 76.94
Week 156-35.0 ± NA
End of Trial (Week 160)-54.0 ± 70.30
SecondaryEuroQol 5 Dimensions 5 Levels (EQ-5D-5L)

EuroQol 5 dimensions 5 levels (EQ-5D-5L) by visit. Count of participants per arm, or severity level of dimension. Measures 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Score ranges from 5-25 with lower score=better outcome, and higher score means a worse outcome.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Count of participants · Participants
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L)
ParticipantsNo ProblemSlight ProblemModerate ProblemSevere ProblemExtreme Problem
Baseline: Anxiety/Depression128431
Baseline: : Mobility2101150
Baseline: : Pain/Discomfort451540
Baseline: : Self-Care1210501
Baseline: : Usual Activities571240
Week 13 Anxiety/Depression166510
Week 13 : Mobility771211
Week 13 : Pain/Discomfort412831
Week 13 : Self-Care187201
Week 13 : Usual Activities615502
Week 26 Anxiety/Depression166500
Week 26 : Mobility561240
Week 26 : Pain/Discomfort811521
Week 26 : Self-Care177300
Week 26 : Usual Activities613710
Week 56 Anxiety/Depression145411
Week 56 : Mobility66490
Week 56 : Pain/Discomfort68920
Week 56 : Self-Care166210
Week 56: Usual Activities89530
Week 78 Anxiety/Depression126321
Week 78 : Mobility58821
Week 78 : Pain/Discomfort414510
Week 78 : Self-Care156210
Week 78 : Usual Activities512610
Week 104 Anxiety/Depression107401
Week 104 : Mobility451021
Week 104 : Pain/Discomfort58900
Week 104 : Self-Care154120
Week 104 : Usual Activities313420
Week 130 Anxiety/Depression78340
Week 130 : Mobility74830
Week 130 : Pain/Discomfort76540
Week 130 : Self-Care145120
Week 130 : Usual Activities68611
Week 156 Anxiety/Depression00100
Week 156 : Mobility10000
Week 156 : Pain/Discomfort00100
Week 156 : Self-Care10000
Week 156 : Usual Activities01000
End of Study (Week 160) Anxiety/Depression96411
End of Study (Week 160) : Mobility35940
21End of Study (Week 160) : Pain/Discomfort47820
End of Study (Week 160) : Self-Care98310
End of Study (Week 160) : Usual Activities57621
SecondaryEuroquol Visual Analog Scale

Euroquol Visual Analog Scale (EQ VAS): A patient-reported measure. The visual scale is numbered from 0 to 100, participants are directed as follows: "100 means the best health you can imagine, 0 means the worst health you can imagine. Mark an X on the scale to indicate how your health is TODAY." Higher scores mean better outcome, lower scores mean worse outcome.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Mean · score on a scale
Euroquol Visual Analog Scale
score on a scaleElamipretide
Baseline65.29 ± 17.83
Week 1365.44 ± 22.68
Week 2662.70 ± 21.23
Week 5270.52 ± 21.27
Week 7864.88 ± 22.18
Week 10467.23 ± 21.75
Week 13072.18 ± 21.38
Week 15660.00 ± NA
End of Trial (Week 160)60.48 ± 23.28
SecondaryNeuroQOL Fatigue Questionnaire

Change from baseline in NeuroQOL Fatigue Questionnaire by visit. Questionnaire is comprised of 8 questions measuring participants incidence of fatigue affecting activities of daily living. Participants respond by choosing one of the following: 1=never, 2=rarely, 3=sometimes, 4=often, 5=always, with a lower score meaning a better outcome with fatigue affecting participant less, and high score meaning a worse outcome, with fatigue affecting the participant more. Total raw scores range from 8-40. Scores were converted to percentages: range0-100%. Change from baseline score: negative number means improved from baseline, positive number means worsened compared to baseline.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Mean · score on a scale
NeuroQOL Fatigue Questionnaire
score on a scaleElamipretide
Week 13-8.39 ± 16.43
Week 26-9.33 ± 16.40
Week 52-10.88 ± 17.48
Week 78-6.79 ± 17.07
Week 104-8.27 ± 18.61
Week 130-6.77 ± 15.69
Week 15613.00 ± NA
End of Study (Week 21 up to Week 160)-2.67 ± 17.38
SecondaryPatient Global Assessment : Categorical

Patient Global Assessment \[PGA\] Score by Visit, count of participants. Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Count of participants · Participants
Patient Global Assessment : Categorical
ParticipantsElamipretide
Baseline — Excellent1
Baseline — Fair11
Baseline — Good9
Baseline — Poor5
Baseline — Very Good2
Week 13 — Excellent0
Week 13 — Fair6
Week 13 — Good12
Week 13 — Poor2
Week 13 — Very Good6
Week 26 — Excellent1
Week 26 — Fair10
Week 26 — Good8
Week 26 — Poor3
Week 26 — Very Good5
Week 52 — Excellent0
Week 52 — Fair3
Week 52 — Good13
Week 52 — Poor4
Week 52 — Very Good5
Week 78 — Excellent0
Week 78 — Fair7
Week 78 — Good10
Week 78 — Poor4
Week 78 — Very Good3
Week 104 — Excellent0
Week 104 — Fair7
Week 104 — Good8
Week 104 — Poor2
Week 104 — Very Good5
Week 130 — Excellent1
Week 130 — Fair6
Week 130 — Good10
Week 130 — Poor4
Week 130 — Very Good1
Week 156 — Excellent0
Week 156 — Fair1
Week 156 — Good0
Week 156 — Poor0
Week 156 — Very Good0
End of Study End of Study (Week 21 up to Week 160) — Excellent0
End of Study End of Study (Week 21 up to Week 160) — Fair8
End of Study End of Study (Week 21 up to Week 160) — Good9
End of Study End of Study (Week 21 up to Week 160) — Poor3
End of Study End of Study (Week 21 up to Week 160) — Very Good1
SecondaryPatient Global Assessment: Continuous Variable

Patient Global Assessment \[PGA\] Score by Visit, Patient-reported current health status by visit. PGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, lower score means worse outcome.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Mean · score on a scale
Patient Global Assessment: Continuous Variable
score on a scaleElamipretide
Baseline3.61 ± 0.99
Week 133.15 ± 0.88
Week 263.15 ± 0.88
Week 523.24 ± 0.97
Week 783.50 ± 0.93
Week 1043.27 ± 0.94
Week 1303.50 ± 1.01
Week 1564.00 ± NA
End of Trial (Week 160)3.62 ± 0.80
SecondaryWork Limitations Questionnaire

Work Limitations Questionnaire by visit. Comprised of 25 items, in 4 categories, or demands: Mental/Interpersonal, Output Tasks, Physical Tasks, and Time Management, measuring the degree to which employed individuals are experiencing limitations on-the-job due to their health problems, and health-related productivity loss. 1= All of the time (100%), 2= most of the time, 3=some of the time (about 50%), 4=slight bit of time, 5=none of the time (0%), 6=does not apply to my job. (Presenteeism). The WLQ items ask respondents to rate their level of difficulty or ability to perform specific job demands. Scale score range from 0 (limited none of the time=better outcome) to 100 (limited all of the time= worse outcome) and represent the reported amount of time in the prior two weeks respondents were limited on-the-job.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Mean · score on a scale
Work Limitations Questionnaire
score on a scaleElamipretide
Mental/Interpersonal: Baseline67.59 ± 15.58
Mental/Interpersonal: Week 1371.33 ± 20.00
Mental/Interpersonal: Week 2672.00 ± 18.54
Mental/Interpersonal: Week 5275.06 ± 19.37
Mental/Interpersonal: Week 7870.62 ± 20.02
Mental/Interpersonal: Week 10468.57 ± 17.42
Mental/Interpersonal: Week 13066.11 ± 24.77
Mental/Interpersonal: End of Trial (Week 160)74.72 ± 19.66
Output Task: Baseline69.67 ± 20.99
Output Task: Week 1375.20 ± 21.89
Output Task: Week 2675.20 ± 18.16
Output Task: Week 5271.56 ± 18.05
Output Task: Week 7861.50 ± 20.28
Output Task: Week 10459.33 ± 25.85
Output Task: Week 13073.00 ± 22.50
Output Task: End of Trial (Week 160)71.00 ± 19.91
Physical Task: Baseline56.39 ± 23.37
Physical Task Week 1358.67 ± 17.37
Physical Task Week 2655.00 ± 11.57
Physical Task Week 5252.59 ± 14.32
Physical Task Week 7857.78 ± 11.55
Physical Task Week 10456.67 ± 25.53
Physical Task Week 13058.33 ± 23.03
Physical Task: End of Trial (Week 160)58.75 ± 23.03
Time Management Baseline61.60 ± 23.26
Time Management Week 1372.40 ± 21.54
Time Management Week 2668.00 ± 24.25
Time Management Week 5268.89 ± 25.83
Time Management Week 7872.89 ± 21.43
Time Management Week 10456.67 ± 27.76
Time Management Week 13057.71 ± 29.11
Time Management End of Trial (Week 160)68.57 ± 24.92
SecondaryPhysician Global Assessment Score (PhGA) by Visit

Physician Global Assessment- Mean Score by visit. PGA Scale asks physician to rate participant's current health status as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means lower health status, worse outcome; lower score means better health status, better outcome.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Mean · score on a scale
Physician Global Assessment Score (PhGA) by Visit
score on a scaleElamipretide
Baseline3.32 ± 0.61
Week 133.11 ± 0.80
Week 263.00 ± 0.73
Week 522.72 ± 0.84
Week 783.25 ± 0.79
Week 1043.18 ± 0.85
Week 1303.18 ± 0.73
Week 1565.00 ± NA
End of Study (Week 160)3.40 ± 0.60
SecondaryPhysician Global Assessment (PhGA): Categorical

Physician Global Assessment \[PhGA\] Score by Visit, Physician-reported current health status by visit. PhGA Scale is as follows: 1=Excellent, 2=Very good, 3=Good, 4=Fair, and 5=Poor. Total score ranges from 1-5. Higher score means worse health status, means worse outcome.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Count of participants · Participants
Physician Global Assessment (PhGA): Categorical
ParticipantsExcellentFairGoodPoorVery Good
Baseline081811
Week 13071316
Week 26161604
Week 52121219
Week 78081114
Week 104041224
Week 130051313
Week 15600010
End of Study (Week 160)061310
SecondaryPMMSA Individual Items

The PMMSA is a patient-reported outcome measure, assessing a participant's "worst feeling" of 10 symptoms during the last 24 hours: tiredness at rest, tiredness during activities, muscle weakness at rest, muscle weakness during activities, balance, vision, abdominal discomfort, muscle pain, numbness, and headache using a 4-point scale: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Max Score =40= worse outcome, Min score= 10= better outcome on scale. PMMSA Individual Items shows number or participants with mild, moderate, severe or no symptoms at all.

Time frame:
Baseline, Week 13, 26, 52, 104, 156, End of Study (Week 160)
Reported as:
Count of participants · Participants
PMMSA Individual Items
ParticipantsElamipretide
Baseline: Abdominal Discomfort — Mild11
Baseline: Abdominal Discomfort — Moderate5
Baseline: Abdominal Discomfort — Not At All8
Baseline: Abdominal Discomfort — Severe3
Baseline: Balance Problems — Mild5
Baseline: Balance Problems — Moderate16
Baseline: Balance Problems — Not At All1
Baseline: Balance Problems — Severe5
Baseline: Headache — Mild4
Baseline: Headache — Moderate6
Baseline: Headache — Not At All16
Baseline: Headache — Severe1
Baseline: Muscle Pain — Mild6
Baseline: Muscle Pain — Moderate12
Baseline: Muscle Pain — Not At All5
Baseline: Muscle Pain — Severe4
Baseline: Muscle Weakness at Rest — Mild12
Baseline: Muscle Weakness at Rest — Moderate10
Baseline: Muscle Weakness at Rest — Not At All1
Baseline: Muscle Weakness at Rest — Severe3
Baseline:Muscle Weakness during Activities — Mild2
Baseline:Muscle Weakness during Activities — Moderate18
Baseline:Muscle Weakness during Activities — Not At All0
Baseline:Muscle Weakness during Activities — Severe7
Baseline: Numbness — Mild11
Baseline: Numbness — Moderate2
Baseline: Numbness — Not At All11
Baseline: Numbness — Severe3
Baseline: Tiredness at Rest — Mild6
Baseline: Tiredness at Rest — Moderate13
Baseline: Tiredness at Rest — Not At All0
Baseline: Tiredness at Rest — Severe8
Baseline: Tiredness during Activities — Mild5
Baseline: Tiredness during Activities — Moderate13
Baseline: Tiredness during Activities — Not At All0
Baseline: Tiredness during Activities — Severe9
Baseline: Vision Problems — Mild8
Baseline: Vision Problems — Moderate9
Baseline: Vision Problems — Not At All6
Baseline: Vision Problems — Severe4
Week 13:Abdominal Discomfort — Mild6
Week 13:Abdominal Discomfort — Moderate8
Week 13:Abdominal Discomfort — Not At All11
Week 13:Abdominal Discomfort — Severe3
Week 13: Balance Problems — Mild11
Week 13: Balance Problems — Moderate9
Week 13: Balance Problems — Not At All1
Week 13: Balance Problems — Severe7
Week 13: Headache — Mild10
Week 13: Headache — Moderate2
Week 13: Headache — Not At All14
Week 13: Headache — Severe2
Week 13: Muscle Pain — Mild11
Week 13: Muscle Pain — Moderate7
Week 13: Muscle Pain — Not At All7
Week 13: Muscle Pain — Severe3
Week 13: Muscle Weakness at Rest — Mild13
Week 13: Muscle Weakness at Rest — Moderate6
Week 13: Muscle Weakness at Rest — Not At All7
Week 13: Muscle Weakness at Rest — Severe2
Week 13: Muscle Weakness during Activities — Mild10
Week 13: Muscle Weakness during Activities — Moderate9
Week 13: Muscle Weakness during Activities — Not At All3
Week 13: Muscle Weakness during Activities — Severe6
Week 13: Numbness — Mild6
Week 13: Numbness — Moderate6
Week 13: Numbness — Not At All15
Week 13: Numbness — Severe1
Week 13: Tiredness at Rest — Mild14
Week 13: Tiredness at Rest — Moderate10
Week 13: Tiredness at Rest — Not At All2
Week 13: Tiredness at Rest — Severe2
Week 13: Tiredness during Activities — Mild12
Week 13: Tiredness during Activities — Moderate11
Week 13: Tiredness during Activities — Not At All0
Week 13: Tiredness during Activities — Severe5
Week 13: Vision Problems — Mild11
Week 13: Vision Problems — Moderate7
Week 13: Vision Problems — Not At All8
Week 13: Vision Problems — Severe2
Week 26:Abdominal Discomfort — Mild7
Week 26:Abdominal Discomfort — Moderate5
Week 26:Abdominal Discomfort — Not At All13
Week 26:Abdominal Discomfort — Severe2
Week 26: Balance Problems — Mild11
Week 26: Balance Problems — Moderate9
Week 26: Balance Problems — Not At All1
Week 26: Balance Problems — Severe6
Week 26: Headache — Mild13
Week 26: Headache — Moderate1
Week 26: Headache — Not At All12
Week 26: Headache — Severe1
Week 26: Muscle Pain — Mild11
Week 26: Muscle Pain — Moderate7
Week 26: Muscle Pain — Not At All7
Week 26: Muscle Pain — Severe2
Week 26: Muscle Weakness at Rest — Mild13
Week 26: Muscle Weakness at Rest — Moderate4
Week 26: Muscle Weakness at Rest — Not At All7
Week 26: Muscle Weakness at Rest — Severe3
Week 26: Muscle Weakness during Activities — Mild10
Week 26: Muscle Weakness during Activities — Moderate11
Week 26: Muscle Weakness during Activities — Not At All1
Week 26: Muscle Weakness during Activities — Severe5
Week 26: Numbness — Mild7
Week 26: Numbness — Moderate3
Week 26: Numbness — Not At All14
Week 26: Numbness — Severe3
Week 26: Tiredness at Rest — Mild15
Week 26: Tiredness at Rest — Moderate8
Week 26: Tiredness at Rest — Not At All1
Week 26: Tiredness at Rest — Severe3
Week 26: Tiredness during Activities — Mild12
Week 26: Tiredness during Activities — Moderate10
Week 26: Tiredness during Activities — Not At All0
Week 26: Tiredness during Activities — Severe5
Week 26: Vision Problems — Mild6
Week 26: Vision Problems — Moderate9
Week 26: Vision Problems — Not At All7
Week 26: Vision Problems — Severe5
Week 52: Abdominal Discomfort — Mild10
Week 52: Abdominal Discomfort — Moderate2
Week 52: Abdominal Discomfort — Not At All10
Week 52: Abdominal Discomfort — Severe3
Week 52: Balance Problems — Mild10
Week 52: Balance Problems — Moderate9
Week 52: Balance Problems — Not At All1
Week 52: Balance Problems — Severe5
Week 52: Headache — Mild10
Week 52: Headache — Moderate4
Week 52: Headache — Not At All10
Week 52: Headache — Severe1
Week 52: Muscle Pain — Mild8
Week 52: Muscle Pain — Moderate6
Week 52: Muscle Pain — Not At All9
Week 52: Muscle Pain — Severe2
Week 52: Muscle Weakness at Rest — Mild8
Week 52: Muscle Weakness at Rest — Moderate8
Week 52: Muscle Weakness at Rest — Not At All6
Week 52: Muscle Weakness at Rest — Severe3
Week 52: Muscle Weakness during Activities — Mild12
Week 52: Muscle Weakness during Activities — Moderate7
Week 52: Muscle Weakness during Activities — Not At All1
Week 52: Muscle Weakness during Activities — Severe5
Week 52: Numbness — Mild4
Week 52: Numbness — Moderate5
Week 52: Numbness — Not At All13
Week 52: Numbness — Severe3
Week 52:Tiredness at Rest — Mild12
Week 52:Tiredness at Rest — Moderate8
Week 52:Tiredness at Rest — Not At All4
Week 52:Tiredness at Rest — Severe1
Week 52:Tiredness during Activities — Mild12
Week 52:Tiredness during Activities — Moderate10
Week 52:Tiredness during Activities — Not At All0
Week 52:Tiredness during Activities — Severe3
Week 52:Vision Problems — Mild8
Week 52:Vision Problems — Moderate9
Week 52:Vision Problems — Not At All5
Week 52:Vision Problems — Severe3
Week 78: Abdominal Discomfort — Mild11
Week 78: Abdominal Discomfort — Moderate2
Week 78: Abdominal Discomfort — Not At All9
Week 78: Abdominal Discomfort — Severe2
Week 78: Balance Problems — Mild7
Week 78: Balance Problems — Moderate13
Week 78: Balance Problems — Not At All1
Week 78: Balance Problems — Severe3
Week 78: Headache — Mild6
Week 78: Headache — Moderate3
Week 78: Headache — Not At All14
Week 78: Headache — Severe1
Week 78:Muscle Pain — Mild10
Week 78:Muscle Pain — Moderate5
Week 78:Muscle Pain — Not At All7
Week 78:Muscle Pain — Severe2
Week 78: Muscle Weakness at Rest — Mild10
Week 78: Muscle Weakness at Rest — Moderate9
Week 78: Muscle Weakness at Rest — Not At All5
Week 78: Muscle Weakness at Rest — Severe0
Week 78:Muscle Weakness during Activities — Mild8
Week 78:Muscle Weakness during Activities — Moderate9
Week 78:Muscle Weakness during Activities — Not At All2
Week 78:Muscle Weakness during Activities — Severe5
Week 78: Numbness — Mild7
Week 78: Numbness — Moderate3
Week 78: Numbness — Not At All12
Week 78: Numbness — Severe2
Week 78:Tiredness at Rest — Mild11
Week 78:Tiredness at Rest — Moderate8
Week 78:Tiredness at Rest — Not At All1
Week 78:Tiredness at Rest — Severe4
Week 78:Tiredness during Activities — Mild8
Week 78:Tiredness during Activities — Moderate10
Week 78:Tiredness during Activities — Not At All1
Week 78:Tiredness during Activities — Severe5
Week 78: Vision Problems — Mild10
Week 78: Vision Problems — Moderate5
Week 78: Vision Problems — Not At All6
Week 78: Vision Problems — Severe3
Week 104: Abdominal Discomfort — Mild7
Week 104: Abdominal Discomfort — Moderate4
Week 104: Abdominal Discomfort — Not At All10
Week 104: Abdominal Discomfort — Severe1
Week 104:Balance Problems — Mild10
Week 104:Balance Problems — Moderate7
Week 104:Balance Problems — Not At All1
Week 104:Balance Problems — Severe4
Week 104:Headache — Mild5
Week 104:Headache — Moderate2
Week 104:Headache — Not At All14
Week 104:Headache — Severe1
Week 104:Muscle Pain — Mild10
Week 104:Muscle Pain — Moderate7
Week 104:Muscle Pain — Not At All5
Week 104:Muscle Pain — Severe0
Week 104:Muscle Weakness at Rest — Mild10
Week 104:Muscle Weakness at Rest — Moderate6
Week 104:Muscle Weakness at Rest — Not At All4
Week 104:Muscle Weakness at Rest — Severe1
Week 104:Muscle Weakness during Activities — Mild8
Week 104:Muscle Weakness during Activities — Moderate8
Week 104:Muscle Weakness during Activities — Not At All3
Week 104:Muscle Weakness during Activities — Severe3
Week 104:Numbness — Mild5
Week 104:Numbness — Moderate2
Week 104:Numbness — Not At All12
Week 104:Numbness — Severe3
Week 104: Tiredness at Rest — Mild11
Week 104: Tiredness at Rest — Moderate6
Week 104: Tiredness at Rest — Not At All2
Week 104: Tiredness at Rest — Severe3
Week 104:Tiredness during Activities — Mild10
Week 104:Tiredness during Activities — Moderate9
Week 104:Tiredness during Activities — Not At All1
Week 104:Tiredness during Activities — Severe2
Week 104: Vision Problems — Mild7
Week 104: Vision Problems — Moderate5
Week 104: Vision Problems — Not At All5
Week 104: Vision Problems — Severe5
Week 130: Abdominal Discomfort — Mild8
Week 130: Abdominal Discomfort — Moderate1
Week 130: Abdominal Discomfort — Not At All9
Week 130: Abdominal Discomfort — Severe3
Week 130: Balance Problems — Mild8
Week 130: Balance Problems — Moderate7
Week 130: Balance Problems — Not At All1
Week 130: Balance Problems — Severe5
Week 130: Headache — Mild8
Week 130: Headache — Moderate2
Week 130: Headache — Not At All11
Week 130: Headache — Severe0
Week 130: Muscle Pain — Mild7
Week 130: Muscle Pain — Moderate4
Week 130: Muscle Pain — Not At All7
Week 130: Muscle Pain — Severe3
Week 130:Muscle Weakness at Rest — Mild9
Week 130:Muscle Weakness at Rest — Moderate7
Week 130:Muscle Weakness at Rest — Not At All4
Week 130:Muscle Weakness at Rest — Severe1
Week 130: Muscle Weakness during Activities — Mild8
Week 130: Muscle Weakness during Activities — Moderate8
Week 130: Muscle Weakness during Activities — Not At All1
Week 130: Muscle Weakness during Activities — Severe4
Week 130:Numbness — Mild7
Week 130:Numbness — Moderate3
Week 130:Numbness — Not At All11
Week 130:Numbness — Severe0
Week 130:Tiredness at Rest — Mild9
Week 130:Tiredness at Rest — Moderate9
Week 130:Tiredness at Rest — Not At All1
Week 130:Tiredness at Rest — Severe2
Week 130: Tiredness during Activities — Mild9
Week 130: Tiredness during Activities — Moderate10
Week 130: Tiredness during Activities — Not At All0
Week 130: Tiredness during Activities — Severe2
Week 130:Vision Problems — Mild7
Week 130:Vision Problems — Moderate7
Week 130:Vision Problems — Not At All4
Week 130:Vision Problems — Severe3
Week 156: Abdominal Discomfort — Mild1
Week 156: Abdominal Discomfort — Moderate0
Week 156: Abdominal Discomfort — Not At All0
Week 156: Abdominal Discomfort — Severe0
Week 156:Balance Problems — Mild1
Week 156:Balance Problems — Moderate0
Week 156:Balance Problems — Not At All0
Week 156:Balance Problems — Severe0
Week 156 Headache — Mild0
Week 156 Headache — Moderate0
Week 156 Headache — Not At All1
Week 156 Headache — Severe0
Week 156 Muscle Pain — Mild0
Week 156 Muscle Pain — Moderate0
Week 156 Muscle Pain — Not At All0
Week 156 Muscle Pain — Severe1
Week 156: Muscle Weakness at Rest — Mild0
Week 156: Muscle Weakness at Rest — Moderate1
Week 156: Muscle Weakness at Rest — Not At All0
Week 156: Muscle Weakness at Rest — Severe0
Week 156: Muscle Weakness during Activities — Mild0
Week 156: Muscle Weakness during Activities — Moderate0
Week 156: Muscle Weakness during Activities — Not At All0
Week 156: Muscle Weakness during Activities — Severe1
Week 156: Numbness — Mild0
Week 156: Numbness — Moderate1
Week 156: Numbness — Not At All0
Week 156: Numbness — Severe0
Week 156:Tiredness at Rest — Mild0
Week 156:Tiredness at Rest — Moderate0
Week 156:Tiredness at Rest — Not At All0
Week 156:Tiredness at Rest — Severe1
Week 156:Tiredness during Activities — Mild0
Week 156:Tiredness during Activities — Moderate0
Week 156:Tiredness during Activities — Not At All0
Week 156:Tiredness during Activities — Severe1
Week 156:Vision Problems — Mild0
Week 156:Vision Problems — Moderate0
Week 156:Vision Problems — Not At All1
Week 156:Vision Problems — Severe0
End of Study: (Week 160) Abdominal Discomfort — Mild8
End of Study: (Week 160) Abdominal Discomfort — Moderate2
End of Study: (Week 160) Abdominal Discomfort — Not At All6
End of Study: (Week 160) Abdominal Discomfort — Severe4
End of Study: (Week 160) Balance Problems — Mild9
End of Study: (Week 160) Balance Problems — Moderate8
End of Study: (Week 160) Balance Problems — Not At All0
End of Study: (Week 160) Balance Problems — Severe4
End of Study: (Week 160) Headache — Mild9
End of Study: (Week 160) Headache — Moderate5
End of Study: (Week 160) Headache — Not At All7
End of Study: (Week 160) Headache — Severe0
End of Study: (Week 160) Muscle Pain — Mild5
End of Study: (Week 160) Muscle Pain — Moderate9
End of Study: (Week 160) Muscle Pain — Not At All4
End of Study: (Week 160) Muscle Pain — Severe3
End of Study: (Week 160) Muscle Weakness at Rest — Mild8
End of Study: (Week 160) Muscle Weakness at Rest — Moderate7
End of Study: (Week 160) Muscle Weakness at Rest — Not At All4
End of Study: (Week 160) Muscle Weakness at Rest — Severe2
End of Study: (Week 160): Muscle Weakness during Activities — Mild3
End of Study: (Week 160): Muscle Weakness during Activities — Moderate11
End of Study: (Week 160): Muscle Weakness during Activities — Not At All2
End of Study: (Week 160): Muscle Weakness during Activities — Severe5
End of Study: (Week 160) Numbness — Mild5
End of Study: (Week 160) Numbness — Moderate5
End of Study: (Week 160) Numbness — Not At All11
End of Study: (Week 160) Numbness — Severe0
End of Study: (Week 160) Tiredness at Rest — Mild7
End of Study: (Week 160) Tiredness at Rest — Moderate9
End of Study: (Week 160) Tiredness at Rest — Not At All1
End of Study: (Week 160) Tiredness at Rest — Severe4
End of Study: (Week 160) Tiredness during Activities — Mild4
End of Study: (Week 160) Tiredness during Activities — Moderate10
End of Study: (Week 160) Tiredness during Activities — Not At All1
End of Study: (Week 160) Tiredness during Activities — Severe6
End of Study: (Week 160): Vision Problems — Mild3
End of Study: (Week 160): Vision Problems — Moderate9
End of Study: (Week 160): Vision Problems — Not At All6
End of Study: (Week 160): Vision Problems — Severe3
SecondaryTotal Fatigue Score_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

Change from baseline in the Total Fatigue score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 4 symptoms: Tiredness at rest, Tiredness during activities, Muscle weakness at rest, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q1 to Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 4-16; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Mean · score on a scale
Total Fatigue Score_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)
score on a scaleElamipretide
Week 13-15.12 ± 29.33
Week 26-15.06 ± 29.72
Week 52-17.01 ± 25.36
Week 78-13.41 ± 31.05
Week 104-18.65 ± 30.15
Week 130-12.92 ± 31.12
Week 15625.00 ± NA
End of Trial (Week 160)-8.33 ± 33.00
SecondaryTotal Fatigue Score During Activities_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)

Change from baseline in the Total Fatigue during Activities score Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) where participants report their "worst feeling" of 2 symptoms: Tiredness during activities, Muscle weakness during activities, at the end of each treatment period. Total fatigue score is sum of Q2 and Q4 only of PMMSA) and is scored as follows: 1=Not at all, 2=Mild, 3=Moderate, and 4=Severe. Total score range is 2-8; lower score means less fatigue and better outcome, higher score means more fatigue and worse outcome. Raw scores were transformed into percentages: 0-100%. Change from baseline: the lower the score, the better the outcome,=less fatigue; the higher the score, means worse outcome= more fatigue.

Time frame:
Baseline, Month 3, Month 6 and Every 26 weeks for up to 160 weeks
Reported as:
Mean · score on a scale
Total Fatigue Score During Activities_Primary Mitochondrial Myopathy Symptom Assessment (PMMSA)
score on a scaleElamipretide
Week 13-14.20 ± 29.13
Week 26-14.10 ± 28.55
Week 52-17.36 ± 25.76
Week 78-14.49 ± 32.30
Week 104-20.63 ± 28.34
Week 130-15.00 ± 31.94
Week 15633.33 ± NA
End of Trial (Week 160)-8.33 ± 31.30

Adverse events

Collected over Baseline through end of study for up to 260 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elamipretide0/28 (0%)8/28 (28.6%)28/28 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventElamipretide
Pancreatitis acuteGastrointestinal disorders1/28
Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/28
HemiparesisNervous system disorders1/28
SyncopeNervous system disorders1/28
Cerebrovascular accidentVascular disorders1/28
Hereditary optic atrophyCongenital, familial and genetic disorders1/28
DysphagiaGastrointestinal disorders1/28
Ankle fractureInjury, poisoning and procedural complications1/28
Troponin increasedInvestigations1/28
Renal colicRenal and urinary disorders1/28
Most frequent other events
Showing 10 of 79
Most frequent other events
EventElamipretide
Injection site pruritusGastrointestinal disorders21/28
Injection site pruritusGeneral disorders18/28
Injection site massGeneral disorders13/28
Injection site urticariaGeneral disorders13/28
Injection site painGeneral disorders10/28
FallInjury, poisoning and procedural complications10/28
NasopharyngitisInfections and infestations8/28
Injection site swellingGeneral disorders7/28
HeadacheNervous system disorders7/28
Chest painGeneral disorders6/28

Baseline characteristics

All participants for whom Baseline measurements were taken.

Age, Continuous
Age, Continuous(years)Elamipretide
Mean47.8 ± 11.30
Sex: Female, Male
Sex: Female, Male(Participants)Elamipretide
Female24
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Elamipretide
Hispanic or Latino1
Not Hispanic or Latino27
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elamipretide
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White27
More than one race1
Unknown or Not Reported0
Baseline weight
Baseline weight(kg)Elamipretide
Mean65.93 ± 14.614
08

Study locations

4 sites
  • University of California
    San Diego, California 92123, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Mar 2020, 39 months.

Results were first posted in Dec 2021, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2016
First posted
Nov 29, 2016
StartActual
Dec 2016
Primary completionActual
Mar 9, 2020
CompletionActual
Apr 9, 2020
Results first posted
Dec 17, 2021
Last update
Dec 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02976038
Responsible party
Sponsor
First posted
Nov 29, 2016
Start date
Dec 2016
Primary completion
Mar 9, 2020
Completion
Apr 9, 2020
Results posted
Dec 17, 2021
Last update
Dec 17, 2021

Study contacts

Jim Carr, PharmD
study director · Stealth BioTherapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elamipretide

Start the discussion